———. 2011b. Pathway to global product safety and quality. Washington, DC: U.S. Food and Drug Administration.
FDA Subcommittee on Science and Technology. 2007. FDA science and mission at risk: Report of the Subcommittee on Science and Technology. Washington, DC: FDA.
Finch, L. 1999. Soothing syrups and teething powders: Regulating proprietary drugs in Australia, 1860-1910. Medical History 43(1):74-94.
Flexner, A. 1910. Medical education in the United States and Canada. New York: The Carnegie Foundation for the Advancement of Teaching.
GAO (Government Accountability Office). 2008a. Drug safety: Better data management and more inspections are needed to strengthen FDA’s foreign drug inspection program. GAO-08-970. Washington, DC: GAO.
———. 2008b. Medical devices: Challenges for FDA in conducting manufacturer inspections. GAO-08-428T. Washington, DC: GAO.
———. 2010a. Drug safety: FDA has conducted more foreign inspections and begun to improve its information on foreign establishments but more progress is needed. GAO-10-961. Washington, DC: GAO.
———. 2010b. Food and Drug Administration: Response to heparin contamination helped protect public health; controls that were needed for working with external entities were recently added. GAO-11-95. Washington, DC: GAO.
———. 2011. Drug safety: FDA faces challenges overseeing the foreign drug manufacturing supply chain. GAO-11-936T. Washington, DC: GAO.
Gill, L. 2011 March 2. Addressing the challenges of medical device safety in a global environment. Presented at Strengthening Core Elements of Regulatory Systems in Developing Countries: Meeting One, Institute of Medicine, Washington, DC.